Therefore, in the present study, we performed a comprehensive pan-cancer analysis based on several well-known open databases and loss-of-function assays to describe the profile of XCL2, including survival prognosis analysis, genetic alterations, methylation, immune infiltration, and drug sensitivity. Here, XCL2 is linked to cancer.